Cingulate Inc. (NASDAQ:CING) Short Interest Update

Cingulate Inc. (NASDAQ:CING) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 133,400 shares, a growth of 24.8% from the January 31st total of 106,900 shares. Based on an average daily volume of 141,800 shares, the short-interest ratio is presently 0.9 days. Currently, 4.3% of the company’s shares are sold short.

Cingulate Trading Up 1.9 %

Shares of CING opened at $3.83 on Friday. Cingulate has a 1-year low of $1.80 and a 1-year high of $20.83. The firm has a 50-day simple moving average of $4.57 and a two-hundred day simple moving average of $5.01.

Institutional Investors Weigh In On Cingulate

Institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC grew its holdings in shares of Cingulate by 281.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock valued at $212,000 after purchasing an additional 31,746 shares in the last quarter. Geode Capital Management LLC acquired a new position in shares of Cingulate in the fourth quarter valued at approximately $135,000. Jane Street Group LLC acquired a new position in shares of Cingulate in the third quarter valued at approximately $106,000. Finally, AlphaMark Advisors LLC grew its holdings in shares of Cingulate by 50,000.0% in the fourth quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock valued at $25,000 after purchasing an additional 5,000 shares in the last quarter. 41.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Roth Mkm assumed coverage on shares of Cingulate in a research note on Friday, January 10th. They set a “buy” rating and a $12.00 target price on the stock. Roth Capital raised shares of Cingulate to a “strong-buy” rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Cingulate in a research note on Thursday. Finally, Maxim Group upgraded shares of Cingulate from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.